We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MSD's immunotherapy Keytruda (pembrolizumab) more than doubled progression free survival in patients with a specific subtype of advanced bowel cancer, when compared with chemotherapy.